Up a level |
Casara, Patrick, Davidson, James, Claperon, Audrey, Le Toumelin-Braizat, Gaëtane, Vogler, Meike ORCID: 0000-0003-2650-586X, Bruno, Alain, Chanrion, Maïa, Lysiak-Auvity, Gaëlle, Le Diguarher, Thierry, Starck, Jérôme-Benoît et al (show 28 more authors)
(2018)
S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth.
Oncotarget, 9 (28).
pp. 20075-20088.
Henz, Kristina, Al-Zebeeby, Aoula, Basoglu, Marion, Fulda, Simone, Cohen, Gerald M, Varadarajan, Shankar ORCID: 0000-0002-8827-6567 and Vogler, Meike
(2019)
Selective BH3-mimetics targeting BCL-2, BCL-X<sub>L</sub> or MCL-1 induce severe mitochondrial perturbations.
BIOLOGICAL CHEMISTRY, 400 (2).
pp. 181-185.
Al-Zebeeby, Aoula, Vogler, Meike, Milani, Mateus, Richards, Caitlin, Alotibi, Ahoud, Greaves, Georgia, Dyer, Martin JS, Cohen, Gerald M and Varadarajan, Shankar ORCID: 0000-0002-8827-6567
(2019)
Targeting Intermediary Metabolism Enhances The Efficacy Of BH3 Mimetic Therapy In Haematological Malignancies.
Haematologica: the hematology journal, 104 (5).
pp. 1016-1025.
Al-Zebeeby, Aoula, Vogler, Meike, Milani, Mateus, Richards, Caitlin, Alotibi, Ahoud, Greaves, Georgia, Dyer, Martin JS, Cohen, Gerald M and Varadarajan, Shankar ORCID: 0000-0002-8827-6567
(2018)
Targeting intermediary metabolism enhances the efficacy of BH3 mimetic therapy in haematological malignancies.
Haematologica: the hematology journal.